Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Focalpoint Partners, also known as XEIA Venture Partners, is a venture capital firm focused on health and performance technologies. Founded to explore the emerging field of 'Human 3,' the firm invests globally across various sectors, including biotech and AI. They manage a portfolio of 20 companies and emphasize innovative solutions in life sciences and health tech.
XEIA Venture Partners invests in seed to growth equity stages, targeting sectors such as life sciences, artificial intelligence, hardware, software, deep tech, and health tech. Their investment thesis revolves around technologies that contribute to health, wellbeing, and performance, collectively referred to as 'Human 3.'
Notable portfolio companies include Forecast, which develops brain drugs using astrocyte insights; Synchron, focused on advanced brain-computer interfaces; and Coherence, working on neuromodulation for brain cancer treatment. Other companies include TippingPoint, Aperture, and NeuroBionics, all contributing to advancements in brain health and therapies.
Li-Huei Tsai, PhD, Director of MIT's Aging Brain Initiative, is a key figure at Focalpoint Partners, focusing on investments in brain health technologies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.